Skip to NavigationSkip to content

Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal

Published on 14/02/19 at 11:40am

Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant interleukin-2) to Clinigen in a deal worth $210 million, it has emerged.

The agreement breaks down into an initial payment by Clinigen of $120 million, with $60 million to follow deferred over the 12 months following the deal’s completion. The rest will be paid in milestone payments, subject to sales performance.

Under the terms of the deal, Clinigen will gain global rights to its new therapy and become its sole license holder, after it purchased the rights to the drug outside the US in July last year.

Annual revenues of Proleukin have hit approximately $60 million in recent years, according to IQVIA. It is already approved in the US for metastatic melanoma and metastatic renal cell carcinoma.

David Bryant, Chief Business Officer at Clinigen, said of the deal: “Proleukin is an important medicine that has demonstrated complete responses in some patients, with evidence of cancer free survival over 15 years. We believe that its use in emerging treatment regimens will continue to help people fight cancer for years to come.” 

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches